SEATTLE GENETICS, INC.
BOTHELL, WA

⚠ NOTE: This page is outdated.
please follow the link.

SEATTLE GENETICS, INC., Bothell

Seattle Genetics is the largest global oncology biotechnology company based in the Pacific Northwest. We are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability and potency. We have one marketed product, ADCETRIS® (brentuximab vedotin), which is the first in a new class of ADCs, commercially available in 70 countries worldwide for relapsed classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). It is approved for two additional indications in the U.S. With multiple global product opportunities, significant research into advancing ADC technology and an emerging complementary immuno-oncology technology, we are positioned to transform cancer therapy. We have built a strong corporate culture around the values of integrity, scientific excellence, teamwork, innovation and mutual respect. Seattle Genetics embodies an entrepreneurial spirit that advances breakthrough therapies, which is why we are an acknowledged leader today in antibody-drug conjugate technology. In 1998, Clay co-founded Seattle Genetics. It was a time when cancer treatments were dominated by chemotherapies that didn’t differentiate between killing cancer cells and normal cells. His vision was to improve the lives of people with cancer by developing targeted therapies to treat major unmet needs. A scientist by training, Clay built Seattle Genetics on a foundation of scientific innovation, rigorous research and drug development practices as well as a passion for helping patients. He has guided the company to its current leadership position in the field of antibody-drug conjugates (ADCs) and in the 2011 FDA approval of our first ADC product, ADCETRIS® (brentuximab vedotin). Under a collaboration with Takeda Pharmaceutical Company, ADCETRIS is now a global brand that is approved in 70 countries. Seattle Genetics is also advancing a diverse pipeline of proprietary ADCs for the treatment of cancer. Under Clay’s leadership, Seattle Genetics has entered in to multiple strategic licenses for our ADC technology, including with Astellas, Genentech (Roche), AbbVie, GlaxoSmithKline and Pfizer, that have generated more than $375 million to date. Across internal and collaborator programs, there are more than 20 ADCs in clinical development using our technology. Clay has also led Seattle Genetics’ capital-raising activities, securing more than $1.8 billion through public and private financings, including the company’s initial public offering in 2001. Srinivas Akkaraju, M.D., Ph.D., has served as a one of our directors since July 2003. Dr. Akkaraju is a Founder and Managing General Partner at Samsara BioCapital. Previously, from April 2013 to February 2016, he served as a General Partner of Sofinnova Ventures. From January 2009 until April 2013, he served as Managing Director of New Leaf Venture Partners. Previously, he served as a Managing Director at Panorama Capital, LLC, a private equity firm. Prior to co-founding Panorama Capital, he was with J.P. Morgan Partners, which he joined in 2001 and of which he became a Partner in 2005. From October 1998 to April 2001, he was in Business and Corporate Development at Genentech, Inc. (now a wholly owned member of The Roche Group), a biotechnology company, most recently as Senior Manager. Felix J. Baker, Ph.D., has served as a Director of Seattle Genetics since July 2003 and as our lead independent director since February 2005. Dr. Baker is a Co-Managing Member of Baker Bros. Advisors LP. Dr. Baker and his brother, Julian Baker, started their fund management careers in 1994 when they co-founded a biotechnology investing partnership with the Tisch Family. In 2000, they founded Baker Bros. Advisors LP. David W. Gryska joined our Board of Directors in March 2005. Since October 2014, Mr. Gryska has served as Executive Vice President and Chief Financial Officer of Incyte Corporation, a biopharmaceutical company. He served as Chief Operating Officer and a director of Myrexis, Inc. from May 2012 to December 2012. From December 2006 to October 2010, he served as Senior Vice President and Chief Financial Officer of Celgene Corporation. From October 2004 to December 2006, he was a principal at Strategic Consulting Group, where he provided strategic consulting to early-stage biotechnology companies. Previously, Mr. Gryska served at Scios, Inc., as Senior Vice President and Chief Financial Officer from 2000 to 2004, and as Vice President of Finance and Chief Financial Officer from 1998 to 2000. Scios was acquired by Johnson & Johnson in 2003. From 1993 to 1998, he served as Vice President, Finance and Chief Financial Officer at Cardiac Pathways, a medical device company later acquired by Boston Scientific Corporation. Prior to Cardiac Pathways, Mr. Gryska served as a partner at Ernst & Young (EY). During his eleven years at EY, he focused on technology industries, with an emphasis on biotechnology and healthcare companies. Marc E. Lippman, M.D., has served as a Director of Seattle Genetics since June 2000. Since May 2007, Dr. Lippman has served as the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Leonard M. Miller School of Medicine, where he also serves as the Deputy Director of the Sylvester Comprehensive Cancer Center. Previously, he served as the John G. Searle Professor and Chairman of the Department of Internal Medicine at the University of Michigan School of Medicine. Before that, Dr. Lippman was the Director of the Lombardi Cancer Research Center, Professor and Chairman of the Department of Oncology, and Professor of Medicine at Georgetown University Medical School. He also served as Chief of the Division of Hematology-Oncology at Georgetown University Medical School and Head of the Medical Breast Cancer Section of the Medicine Branch of the National Cancer Institute.

KEY FACTS ABOUT SEATTLE GENETICS, INC.

Company name
SEATTLE GENETICS, INC.
Status
Active
Filed Number
F11000000297
FEI Number
NOT APPLICABLE
Date of Incorporation
January 24, 2011
Age - 14 years
Home State
DE
Company Type
Foreign for Profit

CONTACTS

Website
http://seattlegenetics.com
Phones
(425) 527-4000
(403) 406-6300
(855) 473-2436
(800) 461-9330

SEATTLE GENETICS, INC. NEAR ME

Principal Address
21823 30th Drive S.E.,
Bothell,
WA,
98021,
US

THIS BUSINESS IN SOCIAL MEDIA

Twitter
Follow

See Also

Officers and Directors

The SEATTLE GENETICS, INC. managed by the three persons from Bothell on following positions: Dire

Daniel G Welch

Position
Dire Active
From
Bothell, WA, 98021

Nancy A Simonian, M.D.

Position
Dire Active
From
Bothell, WA, 98021

John A Orwin

Position
Dire Active
From
Bothell, WA, 98021





Registered Agent is C T CORPORATION SYSTEM

Address
C/O CT CORPORATION SYSTEM, PLANTATION, FL, 33324

Events

October 9, 2020
NAME CHANGE AMENDMENT

Annual Reports

2020
May 28, 2020
2019
March 22, 2019